Create a future where DNA is no longer destiny. Join Rocket Pharma. Rocket Pharma is a fully integrated, late-stage biotechnology company advancing gene therapies with curative potential for patients with rare and life-threatening diseases. We are a team of creative, compassionate, and driven individuals united by a profound mission of seeking gene therapy cures. Rocket places tremendous value on our people and fosters a collaborative environment where bold ideas thrive and every team member makes a meaningful impact. Our core values guide everything we do: we trust one another, show generosity toward patients, embrace curiosity, and strive to elevate science. Team members receive a competitive total rewards package, including equity participation, 401(k) matching, and excellent health benefits. Position Summary As Rocket prepares for continued growth, they are at an inflection point where a senior level regulatory affairs leader will be pivotal. The incoming Senior Vice President (SVP), Regulatory Affairs will be a key member of the senior leadership team, reporting to the Chief Medical Officer. The SVP will develop and drive regulatory strategies to progress Rocket's innovative pipeline of first-in-class adeno-associated viral vector (AAV) and lentiviral vector (LVV) gene therapies. The ideal candidate will be a dynamic, and astute senior regulatory strategy leader with demonstrated expertise in the rapidly evolving gene therapy industry. This is an opportunity for the successful candidate to make an impact in a critical part of the business. This includes careful evaluation of regulatory and drug development risks or gaps and developing contingency plans with a focus on efficiency and planning for first in human and proof of concept studies through registration. The incoming SVP will be a trusted partner to the leadership team and will be critical to driving Rocket Pharmaceuticals’ development and leadership in regulatory affairs. The SVP of Regulatory Affairs will be responsible for leading and implementing strategic and operational regulatory plans for the development of current and future indications. They will play an important role in maintaining effective communication and fostering critical relationships with internal/external collaborators as well as regulatory authorities. This role provides the unique opportunity to design and guide regulatory pathways across an innovative portfolio of early to pivotal-stage gene therapy assets. As the company continues to scale, the incumbent will have the ability to contribute to the organizational build and directly impact patients’ lives by gaining approval for, and delivering on, critical gene therapy products for rare and undertreated diseases.